JP2002532382A - 高血圧を処置する方法およびそこでの使用のための組成物 - Google Patents

高血圧を処置する方法およびそこでの使用のための組成物

Info

Publication number
JP2002532382A
JP2002532382A JP2000568511A JP2000568511A JP2002532382A JP 2002532382 A JP2002532382 A JP 2002532382A JP 2000568511 A JP2000568511 A JP 2000568511A JP 2000568511 A JP2000568511 A JP 2000568511A JP 2002532382 A JP2002532382 A JP 2002532382A
Authority
JP
Japan
Prior art keywords
vegf
hypertension
native
agonist
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000568511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532382A5 (cg-RX-API-DMAC7.html
Inventor
ジョージ エフ. シュライナー,
リチャード ジェイ. ジョンソン,
Original Assignee
サイオス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイオス インコーポレイテッド filed Critical サイオス インコーポレイテッド
Publication of JP2002532382A publication Critical patent/JP2002532382A/ja
Publication of JP2002532382A5 publication Critical patent/JP2002532382A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000568511A 1998-09-09 1999-09-09 高血圧を処置する方法およびそこでの使用のための組成物 Pending JP2002532382A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27
US60/099,694 1999-03-27
US60/126,406 1999-03-27
US60/126,615 1999-03-27
PCT/US1999/020481 WO2000013703A2 (en) 1998-09-09 1999-09-09 Methods of treating hypertension and compositions for use therein

Publications (2)

Publication Number Publication Date
JP2002532382A true JP2002532382A (ja) 2002-10-02
JP2002532382A5 JP2002532382A5 (cg-RX-API-DMAC7.html) 2006-10-26

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000568511A Pending JP2002532382A (ja) 1998-09-09 1999-09-09 高血圧を処置する方法およびそこでの使用のための組成物
JP2000568510A Pending JP2002524421A (ja) 1998-09-09 1999-09-09 微小血管障害の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2000568510A Pending JP2002524421A (ja) 1998-09-09 1999-09-09 微小血管障害の処置

Country Status (13)

Country Link
US (3) US6352975B1 (cg-RX-API-DMAC7.html)
EP (2) EP1112083B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532382A (cg-RX-API-DMAC7.html)
AT (2) ATE253934T1 (cg-RX-API-DMAC7.html)
AU (2) AU5910599A (cg-RX-API-DMAC7.html)
BR (2) BR9913533A (cg-RX-API-DMAC7.html)
CA (2) CA2340728C (cg-RX-API-DMAC7.html)
DE (2) DE69912815T2 (cg-RX-API-DMAC7.html)
DK (2) DK1112083T3 (cg-RX-API-DMAC7.html)
ES (2) ES2211165T3 (cg-RX-API-DMAC7.html)
IL (2) IL141686A0 (cg-RX-API-DMAC7.html)
PT (2) PT1109571E (cg-RX-API-DMAC7.html)
WO (2) WO2000013702A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド eNOS活性の調節とその治療的使用
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002317333C1 (en) 2001-08-01 2009-06-25 University Of Bristol VEGF isoform
US7432301B2 (en) * 2001-08-20 2008-10-07 University Of Virginia Patent Foundation Use of S-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1964568B1 (en) * 2005-08-31 2014-03-26 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of d-allose
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
WO2018183625A1 (en) 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ES2103740T3 (es) 1989-03-24 1997-10-01 Univ California Factor de crecimiento celular endotelialico, su aislamiento y su expresion.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
AU729420B2 (en) * 1996-11-01 2001-02-01 Eurogene Limited Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Also Published As

Publication number Publication date
BR9913564A (pt) 2001-05-22
DK1109571T3 (da) 2004-06-21
EP1112083B1 (en) 2003-11-12
US20020193288A1 (en) 2002-12-19
WO2000013703A9 (en) 2000-06-02
ATE260675T1 (de) 2004-03-15
EP1109571A2 (en) 2001-06-27
CA2340728A1 (en) 2000-03-16
IL141686A0 (en) 2002-03-10
JP2002524421A (ja) 2002-08-06
CA2340728C (en) 2007-11-27
US6352975B1 (en) 2002-03-05
US20040224885A1 (en) 2004-11-11
ATE253934T1 (de) 2003-11-15
DE69912815T2 (de) 2004-10-21
DK1112083T3 (da) 2004-03-08
WO2000013703A2 (en) 2000-03-16
ES2216630T3 (es) 2004-10-16
EP1112083A2 (en) 2001-07-04
PT1109571E (pt) 2004-05-31
AU5910599A (en) 2000-03-27
DE69915310D1 (de) 2004-04-08
ES2211165T3 (es) 2004-07-01
CA2340320A1 (en) 2000-03-16
PT1112083E (pt) 2004-03-31
DE69912815D1 (de) 2003-12-18
CA2340320C (en) 2006-11-14
EP1109571B1 (en) 2004-03-03
IL141687A0 (en) 2002-03-10
WO2000013702A2 (en) 2000-03-16
WO2000013702A9 (en) 2000-10-19
DE69915310T2 (de) 2005-03-10
BR9913533A (pt) 2001-06-05
WO2000013702A3 (en) 2000-09-08
WO2000013703A3 (en) 2000-07-06
AU6028599A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
EP1109571B1 (en) Methods of treating salt-dependent hypertension
EP0914146B1 (en) Morphogen treatment for chronic renal failure
US7030083B2 (en) Treatment of eclampsia and preeclampsia
EP1259248B1 (en) Methods for treating cancers expressing vascular endothelial growth factor d
US5997868A (en) Inhibition of scatter factor for blocking angiogenesis
US7147852B2 (en) Methods for reducing TGF-β production and for promoting repair of liver damage
JP2007197455A (ja) 骨疾患を処置するための骨形成タンパク質
US20020102260A1 (en) Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
Tesch et al. Role of interleukin-1 in mesangial cell proliferation and matrix deposition in experimental mesangioproliferative nephritis
US6677300B1 (en) Treatment of microvascular angiopathies
EP1417971A2 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
US7172757B2 (en) Method of treating fibroproliferative disorders
EP1519193B1 (en) Methods for detecting cancers expressing vascular endothelial growth factor D
AU2006203851B8 (en) Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
EP1447089A2 (en) Methods of treating hypertension and compositions for use therein
HK1068788A (en) Methods of treating hypertension and compositions for use therein
EP1660135B1 (en) Method of treating hepatocellular carcinoma
AU767112B2 (en) Morphogen treatment for chronic renal failure
HK1065947A (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
JP2002161049A (ja) 血管内膜肥厚抑制剤
US20110110953A1 (en) Compound and method for treatment of chronic transplant rejection
HK1132912A1 (zh) 肌肉再生促进剂
HK1132912B (en) Muscle regeneration promoter

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100301